Impaired whole blood thrombin generation is associated with procedure-related bleeding in acutely decompensated cirrhosis
- PMID: 39672204
- DOI: 10.1016/j.jhep.2024.12.008
Impaired whole blood thrombin generation is associated with procedure-related bleeding in acutely decompensated cirrhosis
Abstract
Background & aims: The clinical utility of thrombomodulin-modified thrombin generation (TM-TG) in cirrhosis is uncertain. We conducted a prospective study to evaluate the prognostic value of TM-TG in cirrhosis.
Methods: Patients were recruited during outpatient clinics (compensated and stable decompensated cirrhosis) or if admitted to our inpatient service (acutely decompensated cirrhosis). We performed whole blood (WB) and platelet-poor plasma (PPP) TM-TG at recruitment. All patients were prospectively followed-up for bleeding/thrombosis, hepatic decompensation, and liver-related death.
Results: We included 231 patients: 80 with compensated, 70 with stable decompensated, and 81 with acutely decompensated cirrhosis. Median follow-up was 414 days (range: 77-668). Eleven patients, all with acutely decompensated cirrhosis, experienced procedure-related bleeding. Both WB-TG and PPP-TG were more altered in bleeding vs. non-bleeding individuals (lower endogenous thrombin potential [ETP] and peak-height). However, only WB-TG could identify - at the individual patient level - those experiencing major bleeding (all having pre-procedural ETP <350 nmol/L∗min). In acutely decompensated cirrhosis, the AUC of WB-TG ETP for bleeding was 0.854 (95% CI 0.732-0.976), which was higher than that of PPP-TG ETP (0.676; 95% CI 0.524-0.809). Neither WB-TG nor PPP-TG could predict development of thrombosis, mostly portal vein thrombosis (n = 15). In compensated cirrhosis, WB-TG and PPP-TG were comparable between patients who experienced decompensation and those who did not. In decompensated cirrhosis, WB-TG and PPP-TG were more significantly altered in patients experiencing further decompensation/ACLF/liver-related death. A higher WB-TG ETP was linked to a lower risk of progression independently of MELD, Child-Pugh, and C-reactive protein (hazard ratio 0.4, 95% CI 0.21-0.79, p <0.01).
Conclusions: In compensated cirrhosis, WB-TG and PPP-TG do not improve risk stratification. In decompensated cirrhosis, WB-TG may be a promising tool for estimating procedure-related bleeding risk.
Impact and implications: Thrombomodulin-modified thrombin generation (TM-TG) in cirrhosis is a well-established research tool to assess the complex coagulopathy of cirrhosis; however, its clinical utility is uncertain. In acutely decompensated cirrhosis, a TM-modified whole blood (WB)-TG ETP <350 nmol/L∗min predicted major bleeding after invasive procedures, whereas platelet-poor plasma TG indicated a hypo-coagulable state in bleeding patients but could not identify those at risk. Neither WB-TG nor platelet-poor plasma-TG could predict development of portal vein thrombosis, which was predicted by cirrhosis and portal hypertension severity. In decompensated cirrhosis, a better WB-TG capacity was associated with a lower risk of further decompensation, acute-on-chronic liver failure, and liver-related death independently of MELD score/Child-Pugh stage and C-reactive protein.
Keywords: bleeding; coagulation; hemostasis; liver; thrombosis.
Copyright © 2024 The Author(s). Published by Elsevier B.V. All rights reserved.
Conflict of interest statement
Conflict of interest AZ, EC, CB, Sg, GN, ST, PB, FPR, MS, PS have nothing to disclose. RW, JK, MR, BdL are employees of Synapse Research Institute, part of Diagnostica Stago. Please refer to the accompanying ICMJE disclosure forms for further details.
Similar articles
-
Whole blood thrombin generation shows a significant hypocoagulable state in patients with decompensated cirrhosis.J Thromb Haemost. 2024 Feb;22(2):480-492. doi: 10.1016/j.jtha.2023.10.008. Epub 2023 Oct 21. J Thromb Haemost. 2024. PMID: 37866518
-
Severity of systemic inflammation is the main predictor of ACLF and bleeding in individuals with acutely decompensated cirrhosis.J Hepatol. 2023 Feb;78(2):301-311. doi: 10.1016/j.jhep.2022.09.005. Epub 2022 Sep 21. J Hepatol. 2023. PMID: 36150575
-
Fresh frozen plasma transfusion in patients with cirrhosis and coagulopathy: Effect on conventional coagulation tests and thrombomodulin-modified thrombin generation.J Hepatol. 2020 Jan;72(1):85-94. doi: 10.1016/j.jhep.2019.09.008. Epub 2019 Sep 16. J Hepatol. 2020. PMID: 31536747
-
AGA Clinical Practice Update: Coagulation in Cirrhosis.Gastroenterology. 2019 Jul;157(1):34-43.e1. doi: 10.1053/j.gastro.2019.03.070. Epub 2019 Apr 12. Gastroenterology. 2019. PMID: 30986390 Review.
-
Unravelling the coagulation paradox in liver cirrhosis: challenges and insights.Acta Clin Belg. 2024 Dec;79(6):451-461. doi: 10.1080/17843286.2025.2469906. Epub 2025 Feb 21. Acta Clin Belg. 2024. PMID: 39981790 Review.
Cited by
-
Beyond the Limits of Conventional Coagulation Tests: A Comprehensive Overview of ACLF-Related Coagulopathies.J Clin Med. 2025 May 18;14(10):3539. doi: 10.3390/jcm14103539. J Clin Med. 2025. PMID: 40429533 Free PMC article. Review.
-
Prediction and prevention of post-procedural bleedings in patients with cirrhosis.Clin Mol Hepatol. 2025 Feb;31(Suppl):S205-S227. doi: 10.3350/cmh.2024.0928. Epub 2025 Feb 18. Clin Mol Hepatol. 2025. PMID: 39962975 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous